Mode
Text Size
Log in / Sign up

Spanish RSBQ Validation in 51 Latin American Rett Syndrome Caregivers

Spanish RSBQ Validation in 51 Latin American Rett Syndrome Caregivers
Photo by micheile henderson / Unsplash
Key Takeaway
Consider this Spanish RSBQ translation for research inclusion, noting preliminary validation and need for further clinical assessment.

This observational linguistic validation study assessed a Spanish translation of the Rett Syndrome Behaviour Questionnaire (RSBQ) in 51 Spanish-speaking caregivers of individuals with Rett Syndrome across Latin America (Argentina, Mexico, Peru). The virtual administration aimed to establish comprehension and cultural/linguistic equivalence compared with the original British English RSBQ.

All 51 caregivers completed both surveys. Caregiver comprehension and engagement were reported as high across countries. Test-retest responses were highly correlated between timepoints. No question showed biased response distributions. For test-retest intervals exceeding 80 days, a slight effect on correlation was observed, potentially indicating natural disease progression as a confounder.

Safety and tolerability were not reported, as this was a linguistic assessment without drug exposure. Key limitations include the small sample size (n=51), potential confounding by disease progression in long intervals, and the preliminary nature of the validation.

These results enable broader inclusion of Spanish-speaking populations in Rett Syndrome research and clinical assessments. However, the findings are preliminary and require further clinical validation before broader clinical use.

Study Details

Study typePhase2
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Rett Syndrome (RTT) is a severe neurodevelopmental disorder affecting approximately 1 in 10,000 live female births worldwide. The Rett Syndrome Behaviour Questionnaire (RSBQ), remains one of the most widely used standardized behavioral assessment tools for RTT. However, the RSBQ was originally validated only in British English, limiting its applicability for Spanish-speaking caregivers and clinical centers across Latin America and Spain. Objective: The primary aim of this study was to develop and validate the comprehension of the Spanish translation of the RSBQ to ensure cultural and linguistic equivalence, enhance data reliability, and facilitate earlier, more accurate clinical assessments among Spanish-speaking RTT populations. Methods: Surveys were administered in two phases to Spanish-speaking caregivers between November 2023 and September 2025. Phase I consisted of 12 guided survey administrations with participants being able to ask clarifying questions and offer linguistic modifications of RSBQ questions. Phase II consisted of independent online administration of the refined Spanish RSBQ and a retest at least 7 days later. Participants were recruited through direct outreach and supported virtually during questionnaire completion. Results: Following data cleaning and quality control, a total of 51 caregivers successfully completed both surveys. The Spanish RSBQ demonstrated high caregiver comprehension and strong engagement across multiple Latin American countries, including Argentina, Mexico, and Peru. Responses were highly correlated between test and retest timepoints, and no question showed biased response distributions. A slight effect of response interval on test-retest correlation was observed, potentially indicating the impact of natural disease progression confounding retest evaluation for long (>80 day) intervals; however this effect did not impact the overall linguistic validation results as analysis of only <21 day test-retest responders confirmed the findings. Conclusions: This linguistic validation study represents the first formal step toward the clinical validation of the Spanish RSBQ, enabling broader inclusion of Spanish-speaking populations in RTT research. The collaborative, bilingual data collection strategy proved both feasible and effective, paving the way for multinational trials and expanding therapeutic accessibility through localized, patient-centered innovation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.